Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | PDXK | O00764 | 1/20 | 0.34 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23214682 | 0.91 | TSHR (0.37) | AHRALOX15ALOX12PDXKKLF10 | |
| SCHEMBL5504180 | 0.84 | MEN1 (0.45) | AHRALOX15ALOX12ANO1SNCA | |
| SCHEMBL1903236 | 0.81 | HSD17B10 (0.50) | ALOX15ALOX12PDXKKLF10PKM | |
| SCHEMBL17667561 | 0.77 | AHR (0.35) | AHRNOTUM | |
| SCHEMBL17601428 | 0.77 | AHR (0.40) | AHRALOX15NOTUMHSD17B10 | |
| SCHEMBL15320818 | 0.76 | ANO1 (0.35) | AHRALOX15ALOX12ANO1SNCA | |
| SCHEMBL30574768 | 0.76 | PTPN1 (0.37) | ALOX15ALOX12KLF10PKMSNCA | |
| SCHEMBL1773032 | 0.76 | PTPN1 (0.37) | ALOX15ALOX12KLF10PKMSNCA | |
| SCHEMBL3367771 | 0.75 | AHR (0.36) | AHRALOX15ALOX12NOTUMHPGD | |
| SCHEMBL23214749 | 0.74 | LMNA (0.48) | ALOX15ALOX12PDXKKLF10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | AHR 4/4885ALOX15 1932/4885ALOX12 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.